1. Home
  2. ESPR
  3. ESPR News

Latest Esperion Therapeutics Inc. (ESPR) News on March 14, 2025

ESPR's Q4 Loss Narrower Than Expected, Revenues Increase Y/Y
ESPR

Zacks

9 days ago

ESPR's Q4 Loss Narrower Than Expected, Revenues Increase Y/Y

ESPR

Thomson Reuters StreetEvents

9 days ago

Q4 2024 Esperion Therapeutics Inc Earnings Call

Esperion Therapeutics (ESPR) Reports Q4 Loss, Lags Revenue Estimates
ESPR

Zacks

10 days ago

Esperion Therapeutics (ESPR) Reports Q4 Loss, Lags Revenue Estimates

ESPR

Associated Press Finance

10 days ago

Esperion Therapeutics: Q4 Earnings Snapshot

Esperion Reports Fourth Quarter and Full Year 2024 Financial Results
ESPR

GlobeNewswire

10 days ago

Esperion Reports Fourth Quarter and Full Year 2024 Financial Results

Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia
ESPR

GlobeNewswire

11 days ago

Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia

Is Esperion Therapeutics, Inc. (ESPR) the Best Small Cap Pharma Stocks to Buy Now?
ESPR

Insider Monkey

13 days ago

Is Esperion Therapeutics, Inc. (ESPR) the Best Small Cap Pharma Stocks to Buy Now?

Xeris Biopharma (XERS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
ESPR

Zacks

16 days ago

Xeris Biopharma (XERS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Will Esperion Therapeutics (ESPR) Report Negative Earnings Next Week? What You Should Know
ESPR

Zacks

17 days ago

Will Esperion Therapeutics (ESPR) Report Negative Earnings Next Week? What You Should Know

Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4
ESPR

GlobeNewswire

24 days ago

Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ESPR

GlobeNewswire

a month ago

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Ardelyx (ARDX) Moves 16.0% Higher: Will This Strength Last?
ESPR

Zacks

2 months ago

Ardelyx (ARDX) Moves 16.0% Higher: Will This Strength Last?

Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET.
ESPR

GlobeNewswire

2 months ago

Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET.

Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference
ESPR

GlobeNewswire

2 months ago

Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference

ESPR

MT Newswires

3 months ago

Esperion Therapeutics Completes Financing Deals to Partially Repay Convertible Debt

Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions
ESPR

GlobeNewswire

3 months ago

Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions

ESPR

MT Newswires

3 months ago

Cantor Fitzgerald Initiates Esperion Therapeutics at Overweight With $8 Price Target

ESPR

MT Newswires

3 months ago

Esperion Swaps New Notes, Cash for $210 Million of Convertible Debt; Shares Slump Pre-Bell

Esperion Announces $210 Million Convertible Debt Financing
ESPR

GlobeNewswire

3 months ago

Esperion Announces $210 Million Convertible Debt Financing

ESPR

MT Newswires

3 months ago

Esperion Therapeutics Signs Licensing Deal for Nexletol, Nexlizet in Israel

Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel
ESPR

GlobeNewswire

3 months ago

Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel

ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada
ESPR

Zacks

3 months ago

ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada

ESPR

MT Newswires

3 months ago

Esperion Therapeutics Files Applications for Non-Statin Medications in Canada

Esperion Announces New Drug Submissions in Canada for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk
ESPR

GlobeNewswire

3 months ago

Esperion Announces New Drug Submissions in Canada for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk

ESPR

MT Newswires

4 months ago

Esperion Therapeutics' Bempedoic Acid Submitted for Approval in Japan by Otsuka Pharmaceutical

Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia
ESPR

GlobeNewswire

4 months ago

Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia

Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference
ESPR

GlobeNewswire

4 months ago

Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference

Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024
ESPR

GlobeNewswire

4 months ago

Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ESPR

GlobeNewswire

4 months ago

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Esperion Therapeutics Inc (ESPR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ...
ESPR

GuruFocus.com

4 months ago

Esperion Therapeutics Inc (ESPR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ...

Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y
ESPR

Zacks

4 months ago

Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y

Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates
ESPR

Zacks

4 months ago

Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates

ESPR

Associated Press Finance

4 months ago

Esperion Therapeutics: Q3 Earnings Snapshot

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update
ESPR

GlobeNewswire

4 months ago

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update

Esperion to Participate in Upcoming Jefferies London Healthcare Conference
ESPR

GlobeNewswire

4 months ago

Esperion to Participate in Upcoming Jefferies London Healthcare Conference

Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
ESPR

Zacks

4 months ago

Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions
ESPR

GlobeNewswire

4 months ago

Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions

Esperion to Report Third Quarter 2024 Financial Results on November 7
ESPR

GlobeNewswire

5 months ago

Esperion to Report Third Quarter 2024 Financial Results on November 7

Millennium Management LLC's Strategic Reduction in Esperion Therapeutics Inc Holdings
ESPR

GuruFocus.com

5 months ago

Millennium Management LLC's Strategic Reduction in Esperion Therapeutics Inc Holdings

Is Esperion Therapeutics, Inc. (ESPR) the Best NASDAQ Stock Under $5?
ESPR

Insider Monkey

5 months ago

Is Esperion Therapeutics, Inc. (ESPR) the Best NASDAQ Stock Under $5?

Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid
ESPR

GlobeNewswire

5 months ago

Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid

Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
ESPR

GlobeNewswire

6 months ago

Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report?
ESPR

Zacks

6 months ago

Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report?

Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference
ESPR

GlobeNewswire

6 months ago

Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference

Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)
ESPR

GlobeNewswire

6 months ago

Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)

Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference
ESPR

GlobeNewswire

7 months ago

Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference

ESPR

Thomson Reuters StreetEvents

7 months ago

Q2 2024 Esperion Therapeutics Inc Earnings Call

ESPR

MT Newswires

7 months ago

Esperion Therapeutics Shares Fall After Reporting Wider Than Expected Q2 Loss

Esperion's (ESPR) Q2 Loss Narrows, Revenues Soar Year Over Year
ESPR

Zacks

7 months ago

Esperion's (ESPR) Q2 Loss Narrows, Revenues Soar Year Over Year

Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates
ESPR

Zacks

7 months ago

Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates

ESPR

Associated Press Finance

7 months ago

Esperion Therapeutics: Q2 Earnings Snapshot

Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update
ESPR

GlobeNewswire

7 months ago

Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update

Assertio (ASRT) Reports Q2 Loss, Tops Revenue Estimates
ESPR

Zacks

7 months ago

Assertio (ASRT) Reports Q2 Loss, Tops Revenue Estimates

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ESPR

GlobeNewswire

7 months ago

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
ESPR

Zacks

7 months ago

Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Esperion to Report Second Quarter 2024 Financial Results on August 12
ESPR

GlobeNewswire

8 months ago

Esperion to Report Second Quarter 2024 Financial Results on August 12

Esperion to Participate in Upcoming BTIG Biotech Conference
ESPR

GlobeNewswire

8 months ago

Esperion to Participate in Upcoming BTIG Biotech Conference

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
ESPR

Zacks

8 months ago

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries
ESPR

GlobeNewswire

8 months ago

New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries

ESPR

MT Newswires

8 months ago

Esperion Therapeutics Enters $304.7 Million Royalty Purchase Agreement with OMERS; Shares Rise

PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar
ESPR

BioPharma Dive

9 months ago

PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar

Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility
ESPR

GlobeNewswire

9 months ago

Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility

Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength?
ESPR

Zacks

9 months ago

Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength?

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers
ESPR

GOBankingRates

9 months ago

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers

Bumrah delivers as India beat Pakistan in low-scoring thriller
ESPR

AFP

9 months ago

Bumrah delivers as India beat Pakistan in low-scoring thriller

Italy beat Bosnia in final Euros warm-up
ESPR

AFP

9 months ago

Italy beat Bosnia in final Euros warm-up

Trump loyalists proud to support 'felon' at Las Vegas rally
ESPR

AFP

9 months ago

Trump loyalists proud to support 'felon' at Las Vegas rally

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia
ESPR

Business Insider

9 months ago

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

The Best Woody Perfume For Women
ESPR

Insider Monkey

9 months ago

The Best Woody Perfume For Women

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase
ESPR

Reuters

9 months ago

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase

ESPR

Insider Monkey

9 months ago

Best Date Night Fragrance in 2024

Why Is Catalyst (CPRX) Up 0.7% Since Last Earnings Report?
ESPR

Zacks

9 months ago

Why Is Catalyst (CPRX) Up 0.7% Since Last Earnings Report?

Why Is Esperion Therapeutics (ESPR) Up 14.2% Since Last Earnings Report?
ESPR

Zacks

9 months ago

Why Is Esperion Therapeutics (ESPR) Up 14.2% Since Last Earnings Report?

Esperion's (ESPR) Drugs Get EU Nod for Lowering Heart Risk
ESPR

Zacks

10 months ago

Esperion's (ESPR) Drugs Get EU Nod for Lowering Heart Risk

Esperion to Participate in Upcoming June Investor Conferences
ESPR

GlobeNewswire

10 months ago

Esperion to Participate in Upcoming June Investor Conferences

First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk
ESPR

GlobeNewswire

10 months ago

First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk

ESPR

MT Newswires

10 months ago

Esperion Therapeutics Says Primary Endpoint Achieved in Hypercholesterolemia Treatment Phase 3 Trial; Shares Rise

Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia
ESPR

GlobeNewswire

10 months ago

Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia

Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®
ESPR

GlobeNewswire

10 months ago

Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ESPR

GlobeNewswire

10 months ago

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues
ESPR

Zacks

10 months ago

Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q1 2024 Earnings Call Transcript
ESPR

Insider Monkey

10 months ago

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q1 2024 Earnings Call Transcript

ESPR

GuruFocus.com

10 months ago

Esperion Therapeutics Inc (ESPR) Q1 2024 Earnings Call Transcript Highlights: Soaring Revenues ...

Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars
ESPR

Benzinga

10 months ago

Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars

ESPR

GuruFocus.com

10 months ago

Esperion Therapeutics Inc (ESPR) Surpasses Q1 Revenue Forecasts with a 467% Increase

ESPR

MT Newswires

10 months ago

Top Premarket Gainers

Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Beat Estimates
ESPR

Zacks

10 months ago

Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Beat Estimates

ESPR

Associated Press Finance

10 months ago

Esperion Therapeutics: Q1 Earnings Snapshot

Esperion Reports First Quarter 2024 Financial Results
ESPR

GlobeNewswire

10 months ago

Esperion Reports First Quarter 2024 Financial Results

Esperion to Participate in Upcoming May Investor Conferences
ESPR

GlobeNewswire

10 months ago

Esperion to Participate in Upcoming May Investor Conferences

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
ESPR

Zacks

a year ago

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Esperion to Report First Quarter 2024 Financial Results on May 7
ESPR

GlobeNewswire

a year ago

Esperion to Report First Quarter 2024 Financial Results on May 7

11 Best Low Price Pharma Stocks To Invest In
ESPR

Insider Monkey

a year ago

11 Best Low Price Pharma Stocks To Invest In

Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
ESPR

GlobeNewswire

a year ago

Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity

Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024
ESPR

GlobeNewswire

a year ago

Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024

Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report?
ESPR

Zacks

a year ago

Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report?

Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference
ESPR

GlobeNewswire

a year ago

Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference

Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24
ESPR

GlobeNewswire

a year ago

Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24

U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
ESPR

Business Wire

a year ago

U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
ESPR

GlobeNewswire

a year ago

U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

Share on Social Networks: